Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - Says the results from its study evaluating biomarkers from peanut allergic patients are successful. The tests confirm peanut vaccine candidate's hypoallergic potential. The successful findings support Allergy Therapeutics' VLP Peanut first in-human phase I study design which is on track to start in the first quarter of 2022. The results also strengthen the company's phase I study IND application being submitted to the US Food and Drug Administration in late 2021, the company notes.
The short-course peanut allergy vaccine represents a "significant opportunity in the USD8 billion worldwide food allergy market", Allergy Therapeutics highlights.
"The biomarker study results are encouraging and provide strong support for the human translation of the pre-clinical results and strong confidence in the data to be generated in the planned Phase I study," the company says.
The study aimed to demonstrate the vaccine candidate's hypoallergic potential, meaning it does not illicit an allergic reaction in patients upon dosing.
"We are pleased to have reached this important milestone in the development of our ground-breaking and disruptive vaccine candidate, VLP Peanut," comments Chief Executive Manuel Llobet.
Current stock price: 28.74 pence, up 7.0% Tuesday afternoon
Year-to-date change: up 73%
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Allergy Thera. (AGY)